JP2013542919A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542919A5
JP2013542919A5 JP2013528349A JP2013528349A JP2013542919A5 JP 2013542919 A5 JP2013542919 A5 JP 2013542919A5 JP 2013528349 A JP2013528349 A JP 2013528349A JP 2013528349 A JP2013528349 A JP 2013528349A JP 2013542919 A5 JP2013542919 A5 JP 2013542919A5
Authority
JP
Japan
Prior art keywords
sdrd
clfa
composition
fnbpb
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528349A
Other languages
English (en)
Japanese (ja)
Other versions
JP5793194B2 (ja
JP2013542919A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051079 external-priority patent/WO2012034067A1/en
Publication of JP2013542919A publication Critical patent/JP2013542919A/ja
Publication of JP2013542919A5 publication Critical patent/JP2013542919A5/ja
Application granted granted Critical
Publication of JP5793194B2 publication Critical patent/JP5793194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528349A 2010-09-09 2011-09-09 感染防御ブドウ球菌抗原が関与する方法および組成物 Active JP5793194B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38137210P 2010-09-09 2010-09-09
US61/381,372 2010-09-09
US201161435617P 2011-01-24 2011-01-24
US61/435,617 2011-01-24
PCT/US2011/051079 WO2012034067A1 (en) 2010-09-09 2011-09-09 Methods and compositions involving protective staphylococcal antigens

Publications (3)

Publication Number Publication Date
JP2013542919A JP2013542919A (ja) 2013-11-28
JP2013542919A5 true JP2013542919A5 (enExample) 2014-02-27
JP5793194B2 JP5793194B2 (ja) 2015-10-14

Family

ID=44654513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528349A Active JP5793194B2 (ja) 2010-09-09 2011-09-09 感染防御ブドウ球菌抗原が関与する方法および組成物

Country Status (4)

Country Link
US (1) US9095540B2 (enExample)
EP (1) EP2614074A1 (enExample)
JP (1) JP5793194B2 (enExample)
WO (1) WO2012034067A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US8840906B2 (en) 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
US8821894B2 (en) * 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN104768572B (zh) * 2012-04-26 2021-08-24 芝加哥大学 葡萄球菌凝固酶抗原及其使用方法
MX375324B (es) * 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
SI3122378T1 (sl) * 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
GB201615254D0 (en) * 2016-09-08 2016-11-23 Ge Healthcare Bio Sciences Ab Novel Ligand and use thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN114262720B (zh) * 2021-12-27 2023-07-25 河南兴华生物技术有限公司 杆状病毒表达系统的信号肽及其应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4338298A (en) 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5858652A (en) 1988-08-30 1999-01-12 Abbott Laboratories Detection and amplification of target nucleic acid sequences
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5846709A (en) 1993-06-15 1998-12-08 Imclone Systems Incorporated Chemical process for amplifying and detecting nucleic acid sequences
FR2708288B1 (fr) 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
AU707391B2 (en) 1994-05-28 1999-07-08 Tepnel Medical Limited Producing copies of nucleic acids
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5935825A (en) 1994-11-18 1999-08-10 Shimadzu Corporation Process and reagent for amplifying nucleic acid sequences
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
US5700928A (en) 1995-10-16 1997-12-23 Smithkline Beecham, P.L.C. Polynucleotide encoding saliva binding protein
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
ATE309271T1 (de) 1996-05-16 2005-11-15 Texas A & M Univ Sys Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
US5939291A (en) 1996-06-14 1999-08-17 Sarnoff Corporation Microfluidic method for nucleic acid amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
JP2002514056A (ja) 1996-10-23 2002-05-14 アメリカン・ホーム・プロダクツ・コーポレーション ワクチン
US5849497A (en) 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US5916776A (en) 1997-08-27 1999-06-29 Sarnoff Corporation Amplification method for a polynucleotide
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
CA2339355A1 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
EP1117772B1 (en) 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
CA2344166C (en) 1998-09-14 2008-11-18 Nabi Compositions of .beta.-glucans and specific igiv
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2001034809A2 (en) 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
ATE413191T1 (de) 1999-12-03 2008-11-15 Celltech Chiroscience Ltd Verwendung of interleukin-1 mutein als impfstoffadjuvans
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
EP1333858B8 (en) 2000-11-07 2006-06-14 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002074324A1 (en) 2001-03-15 2002-09-26 The Texas A & M University System Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US7115264B2 (en) 2001-11-05 2006-10-03 Inhibitex Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
CA2469132A1 (en) 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
ES2540771T3 (es) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición de anticuerpos para uso en vacunación contra estafilococos
CN1884302A (zh) 2005-06-24 2006-12-27 中国人民解放军军事医学科学院微生物流行病研究所 一种金黄色葡萄球菌纤连蛋白结合蛋白的融合蛋白,其制备方法及用途
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
WO2007113222A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2960604T3 (es) 2008-01-31 2024-03-05 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Tratamiento de infecciones microbianas
CA2739581A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2011005341A2 (en) * 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
WO2011127032A1 (en) * 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
US8821894B2 (en) * 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants

Similar Documents

Publication Publication Date Title
JP2013542919A5 (enExample)
NZ612315A (en) Compositions for immunising against staphylococcus aureus
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
IN2014KN01715A (enExample)
JP2014530253A5 (enExample)
JP2014051497A5 (enExample)
TWI455721B (zh) 癌疫苗組合物
NZ595063A (en) Polypeptides from neisseria meningitidis
JP2015517488A5 (enExample)
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
JP2018509388A5 (enExample)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
HRP20220068T1 (hr) Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
JP2013501007A5 (enExample)
JP2019533722A5 (enExample)
RU2015132369A (ru) Комбинированная терапия для лечения нозокомиальной пневмонии
JP2015500827A5 (enExample)
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
CN110337304A (zh) 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物